Press Release: Novartis Cosentyx(R) meets primary -2-

Number: 9618241 [Link

https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9618241 ]

12. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P,

Pascale P, Delicha EM, Pricop L, Mpofu S. "Secukinumab Provides Sustained

Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final

5--Year Efficacy and Safety Results from a Phase 3 Trial". ACR/ARHP 2020

Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020);

CONCL--00511 (Secukinumab Provides Sustained Improvements in the Signs

and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase

3 FUTURE 1 Study - PubMed https://pubmed.ncbi.nlm.nih.gov/31943974/ )

13. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG,

Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2

Study Group. "Long--term efficacy and safety of secukinumab in patients

with psoriatic arthritis: 5--year (end--of--study) results from the phase

III FUTURE 2 study." Lancet Rheumatology. 2020; 2(4): e227--e235.

(Long-term efficacy and safety of secukinumab in patients with psoriatic

arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study

https://eprints.whiterose.ac.uk/id/eprint/156560/8/clean%20AAM.pdf )

14. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R,

Patekar M, Charef P, Milutinovic M, Leonardi C, Mrowietz U.Secukinumab

demonstrates high sustained efficacy and a favourable safety profile in

patients with moderate-to-severe psoriasis through 5 years of treatment

(SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018

Sep;32(9):1507--1514. (Secukinumab demonstrates high sustained efficacy

and a favourable safety profile in patients with moderate-to-severe

psoriasis through 5 years of treatment (SCULPTURE Extension Study) -

PubMed https://pubmed.ncbi.nlm.nih.gov/29444376/ )

15. Floris A, et al. Clin Rheumatol. 2022;41(1):19--31.

16. Gabriel SE, et al. Arthritis Rheum. 1997;40(10):1873--8.

17. Hutchings A, et al. Arthritis Rheum. 2007;57(5):803--9;

Espígol-Frigolé G, et al. Lancet.2023;402(10411):1459--72;

Twohig H, et al. Patient Educ Couns. 2015;98(5):645--50.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

October 22, 2025 01:15 ET (05:15 GMT)